In PAD patients with chronic kidney disease who’ve undergone revascularization, rivaroxaban (Xarelto; Bayer/Janssen) can safely reduce major CV and limb events, new findings from the VOYAGER PAD trial suggest.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045